US FDA approves Roche's Gazyva as first treatment for primary membranous nephropathy
What's the deal? On 13 November 2026, the US Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), developed by Genentech, a member of the Roche group, as the first drug specifically for adults with primary membranous nephropathy at risk of disease progression. The approval covers use of the antibody therapy to induce remission of proteinuria — the abnormal leaking of protein into the urine that characterises the disease.
Why it matters: Primary membranous nephropathy is a rare kidney disease in which the immune system attacks the glomeruli, the tiny filters in the kidneys that clean waste from the blood. The resulting inflammation and damage can cause severe swelling, high blood pressure, high cholesterol, fatigue and, in the worst cases, kidney failure. Until now, no treatment had been approved specifically for this condition: patients were managed with off-label medicines such as tacrolimus. Gazyva, an antibody that depletes the immune cells (B cells) driving the attack, gives patients a therapy with regulatory approval behind it.
The evidence: The approval is based on the MAJESTY phase 3 trial (NCT04629248), which randomised 142 adults to Gazyva or tacrolimus over 104 weeks. Complete remission of proteinuria at week 104 was achieved by 36% of patients on Gazyva versus 6% on tacrolimus. Gazyva's label carries a boxed warning over hepatitis B virus reactivation and progressive multifocal leukoencephalopathy (a rare, serious brain infection), and the most common side effects in the study were infusion-related reactions. Gazyva was previously approved for certain blood cancers, active lupus nephritis and childhood-onset idiopathic nephrotic syndrome.
Read more: FDA, 13 November 2026